LOG IN
SIGN UP
MARKET
PTGX
PTGX
Protagonist Ther
NASDAQ
Real-time Quotes | Nasdaq Last Sale
8.20
-0.26
-3.07%
Closed 16:16 07/06 EDT
OPEN
8.44
PREV CLOSE
8.46
HIGH
8.72
LOW
8.14
VOLUME
816.01K
TURNOVER
0
52 WEEK HIGH
50.54
52 WEEK LOW
6.91
MARKET CAP
398.98M
P/E (TTM)
-3.1693
1D
5D
1M
3M
1Y
5Y
MGNI, NRIX and PTGX are among after hour and movers
Gainers: Okta (OKTA) +14%. StoneCo (STNE) +9%. Nurix Therapeutics (NRIX) +5%. Protagonist Therapeutics (PTGX) +5%. MacroGenics (MGNX) +5%. Losers: HashiCorp (HCP) -9%. JOANN (JOAN) -8%. Instil Bio (TIL) -5%. Magnite (MGNI) -5%.
Seekingalpha · 06/02 20:48
NRDS, PTGX and SGMO are among after hour movers
Gainers: Repare Therapeutics (RPTX) +20%. Credo Technology Group Holding (CRDO) +8%. Elevation Oncology (ELEV) +8%. MongoDB (MDB) +6%. Global Blood Therapeutics (GBT) +5%. Losers: Charge Enterprises (CRGE) -5%. NerdWallet (NRDS) -5%. Protagonist
Seekingalpha · 06/01 21:45
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President, and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York on Wednesday, June 8 at 9:30...
PR Newswire · 06/01 20:05
BRIEF-Protagonist Therapeutics To Present Updated Phase 2 Rusfertide Clinical Results In Polycythemia Vera (Pv) At Asco 2022
reuters.com · 05/26 23:55
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera (PV). These results will be shared as an oral presentation at the 2022 American Society of Clini...
PR Newswire · 05/26 21:00
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
marketwatch.com · 05/26 18:20
PTGX, MNKD and AVGO are among after hour movers
Gainers: Protagonist Therapeutics (PTGX) +10%. Marriott International (MAR) +7%. Aurora Innovation (AUR) +6%. MannKind Corporation (MNKD) +5%. Arcimoto (FUV) +5%. Losers: Enanta Pharmaceuticals (ENTA) -15%. Cisco Systems (CSCO) -12%. Limelight Networks (LL...
Seekingalpha · 05/18 21:57
Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
MT Newswires · 05/18 06:57
No Data
Learn about the latest financial forecast of PTGX. Analyze the recent business situations of Protagonist Ther through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
42.86%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PTGX stock price target is 44.17 with a high estimate of 70.00 and a low estimate of 30.00.
Current 8.20
EPS
Actual
Estimate
-0.74-0.56-0.37-0.19
Institutional Holdings
Institutions: 179
Institutional Holdings: 55.45M
% Owned: 113.96%
Shares Outstanding: 48.66M
TypeInstitutionsShares
Increased
54
8.66M
New
21
1.44M
Decreased
47
5.66M
Sold Out
29
3.21M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.29%
Pharmaceuticals & Medical Research
+0.38%
Key Executives
Non-Executive Chairman/Independent Director
Harold Selick
President/Chief Executive Officer/Director
Dinesh Patel
Chief Financial Officer/Executive Vice President
Asif Ali
Other
Suneel Gupta
Other
David Liu
Other
Samuel Saks
Independent Director
Bryan Giraudo
Independent Director
Sarah Noonberg
Independent Director
Sarah O'Dowd
Independent Director
William Waddill
Independent Director
Lewis Williams
No Data
No Data
About PTGX
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.
Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.